JP2012149070A5 - - Google Patents

Download PDF

Info

Publication number
JP2012149070A5
JP2012149070A5 JP2012049012A JP2012049012A JP2012149070A5 JP 2012149070 A5 JP2012149070 A5 JP 2012149070A5 JP 2012049012 A JP2012049012 A JP 2012049012A JP 2012049012 A JP2012049012 A JP 2012049012A JP 2012149070 A5 JP2012149070 A5 JP 2012149070A5
Authority
JP
Japan
Prior art keywords
seq
isolated polypeptide
amino acid
acid sequence
sequence selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012049012A
Other languages
English (en)
Other versions
JP2012149070A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012149070A publication Critical patent/JP2012149070A/ja
Publication of JP2012149070A5 publication Critical patent/JP2012149070A5/ja
Pending legal-status Critical Current

Links

Description

表４に示されているように、野生型ＥＧＦｒ及び１５塩基対の欠失及びＬ８５８Ｒ ＥＧＦｒ変異体に対して、低濃度のＥＧＦｒ自己リン酸化を抑制する上で、ゲフィチニブ及びパニツムマブの両方が有効であった。しかしながら、ゲフィチニブ（ＩＣ５０＞２０００ｎＭ）によって、Ｔ７９０Ｍ変異体ＥＧＦｒポリペプチドの自己リン酸化は阻害されなかったが、パニツムマブ（０．２３ｎＭのＩＣ５０）によって効果的に阻害された。従って、パニツムマブは、ＥＧＦｒエキソン２０中にＴ７９０Ｍ変異を有するＮＳＣＬＣ患者に対して、ゲフィチニブより有効な処置であり得る。

Claims (7)

  1. 配列番号２、配列番号３、配列番号５、配列番号６、配列番号７、配列番号１０、配列番号１２及び配列番号１３から選択されるアミノ酸配列を含む単離されたポリペプチド。
  2. 配列番号２、配列番号３、配列番号５、配列番号６、配列番号７、配列番号９、配列番号１０、配列番号１２及び配列番号１３から選択されるアミノ酸配列からなる単離されたポリペプチド。
  3. 配列番号１５、配列番号１６及び配列番号１７から選択される少なくとも１つのアミノ酸配列を含む単離されたポリペプチド。
  4. 配列番号１５、配列番号１６及び配列番号１７から選択される少なくとも１つのアミノ酸配列からなる単離されたポリペプチド。
  5. 配列番号２０のアミノ酸配列を含む単離されたポリペプチド。
  6. 配列番号２０のアミノ酸配列の単離されたポリペプチド。
  7. 異種ポリペプチドに融合された請求項１〜６の何れかの単離されたポリペプチドを含む融合タンパク質。
JP2012049012A 2005-02-24 2012-03-06 上皮成長因子受容体変異 Pending JP2012149070A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65626305P 2005-02-24 2005-02-24
US60/656,263 2005-02-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007557212A Division JP2008535477A (ja) 2005-02-24 2006-02-23 上皮成長因子受容体変異

Publications (2)

Publication Number Publication Date
JP2012149070A JP2012149070A (ja) 2012-08-09
JP2012149070A5 true JP2012149070A5 (ja) 2013-08-08

Family

ID=36579263

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007557212A Pending JP2008535477A (ja) 2005-02-24 2006-02-23 上皮成長因子受容体変異
JP2012049012A Pending JP2012149070A (ja) 2005-02-24 2012-03-06 上皮成長因子受容体変異

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007557212A Pending JP2008535477A (ja) 2005-02-24 2006-02-23 上皮成長因子受容体変異

Country Status (15)

Country Link
US (2) US7981605B2 (ja)
EP (1) EP1851243A2 (ja)
JP (2) JP2008535477A (ja)
KR (1) KR20070106029A (ja)
CN (1) CN101208354A (ja)
AU (2) AU2006216477A1 (ja)
BR (1) BRPI0607235A2 (ja)
CA (1) CA2601936C (ja)
CR (1) CR9390A (ja)
EA (1) EA013617B1 (ja)
IL (1) IL185210A0 (ja)
MX (1) MX2007009963A (ja)
NO (1) NO20074826L (ja)
WO (1) WO2006091899A2 (ja)
ZA (1) ZA200707379B (ja)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (zh) * 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP2505591A1 (en) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting a drug resistant EGFR mutant
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
DK2132229T3 (en) 2007-03-01 2016-06-20 Symphogen As Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
SI2412828T1 (sl) * 2007-03-13 2013-10-30 Amgen Inc. Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
CN102099668B (zh) * 2008-07-17 2013-05-01 皇家飞利浦电子股份有限公司 纳米孔装置和用于核酸分析的方法
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
EP2475789A4 (en) * 2009-09-09 2013-12-18 Quintiles Transnat Corp METHODS FOR PREDICTING SENSITIVITY OF DISEASE OR DISORDER TO RECEPTOR TYROSINE KINASE INHIBITOR THROUGH MUTATION ANALYSIS IN PIK3CA GENE
EP2592141B1 (en) * 2010-07-07 2015-12-30 Eisai R&D Management Co., Ltd. Method for production of tumor cells from normal mammary epithelial cells
US20120164641A1 (en) * 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
CA2898200A1 (en) * 2013-01-14 2014-07-17 Academia Sinica Dnazyme for silencing the expression of egfr
CN103739713B (zh) * 2013-12-10 2016-03-09 吴炯 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
WO2015092393A2 (en) * 2013-12-17 2015-06-25 Kymab Limited Human targets
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN105779480B (zh) * 2016-03-24 2020-03-20 成都康景生物科技有限公司 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN108047308A (zh) * 2018-02-02 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108047309A (zh) * 2018-02-07 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250268A (zh) * 2018-02-08 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218959A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218960A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108409832A (zh) * 2018-03-07 2018-08-17 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218961A (zh) * 2018-03-19 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440649A (zh) * 2018-05-31 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440650A (zh) * 2018-06-04 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108752424A (zh) * 2018-06-04 2018-11-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440651A (zh) * 2018-06-08 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
KR102310819B1 (ko) * 2019-01-11 2021-10-12 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
WO2020145711A1 (ko) * 2019-01-11 2020-07-16 주식회사 진캐스트 Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR102286025B1 (ko) * 2019-01-11 2021-08-05 주식회사 진캐스트 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법
JP2022521610A (ja) 2019-02-26 2022-04-11 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EP4005593A4 (en) * 2019-07-24 2023-08-16 Sinocelltech Ltd. MULTI-VARIABLE DOSE DELIVERY METHOD FOR USE IN THE TREATMENT OF CANCER IN WHICH EGFR IS STRONGLY EXPRESSED

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
CA2408175A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
US20050277118A1 (en) * 2002-09-11 2005-12-15 Roth Richard B Methods for identifying subjects at risk of melanoma and treatments thereof
ES2741574T3 (es) * 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
EP3042964A1 (en) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
KR20070038557A (ko) * 2004-07-22 2007-04-10 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
WO2006109085A1 (en) * 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
JP2008546421A (ja) 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Ｅｇｆｒおよびｋｒａｓ変異

Similar Documents

Publication Publication Date Title
JP2012149070A5 (ja)
JP2012126742A5 (ja)
EP2470559A4 (en) COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
JP2013519365A5 (ja)
JP2011136997A5 (ja)
TR201903195T4 (tr) Apiksaban formülasyonları.
EP4223772A3 (en) Optimized factor viii gene
EP3310760B8 (en) Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
MX343346B (es) Composición tipo azeotropo de hexafluoropropano, hexafluoropropeno y fluoruro de hidrógeno.
JP2013033930A5 (ja)
EA201500575A1 (ru) Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении
FI20115374A0 (fi) Uudet hypoallergeenit
MX349294B (es) Formulaciones virales liofilizadas.
JP2013529619A5 (ja)
BR112017017609A2 (ja) Fc fusion quantity compatibility IgE receptor alpha chain
WO2015128746A3 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
JP2011136986A5 (ja)
WO2011119716A3 (en) Flavivirus host range mutations and uses thereof
WO2015143512A3 (en) Enhancement of recombinant protein expression with copper
JP2011136980A5 (ja)
JP2013053058A5 (ja)
JP2012524034A5 (ja)
JP2015500295A5 (ja)
RU2008104692A (ru) Рекомбинантная пероксидаза табака nicotiana tabacum